購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
huSPAST-HA-R499H Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huSPAST-HA-R499H Mouse
製品名
huSPAST-HA-R499H Mouse
製品ID
C002144
系統名
C57BL/6Cya-Spasttm2(HA tag-hSPAST*R499H)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「huSPAST-HA-R499H Mouse(カタログ番号C002144)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
FSP2, SPG4, ADPSP
NCBI ID
染色体
Chr 2
MGI ID
さらに
系統詳細
Hereditary spastic paraplegia (HSP) is a hereditary neurodegenerative disease characterized pathologically by retrograde axonal degeneration of the corticospinal tract and the posterior columns of the spinal cord. Its clinical manifestations include progressive spastic weakness of both lower limbs, scissor gait, hyperreflexia, and positive pathological signs. The prevalence of autosomal dominant HSP is approximately 1–5 per 100,000, and it usually begins in young adulthood. SPG4, caused by mutations in the SPAST gene, is the most common autosomal dominant HSP subtype, accounting for about 40% of all autosomal dominant HSP families [1-3], and it is also the most common subtype in Chinese autosomal dominant HSP cohorts [4]. Spastin, encoded by SPAST, is a member of the AAA+ ATPase family. By severing microtubules, it regulates microtubule length, dynamics, and axonal transport, and is essential for maintaining cytoskeletal homeostasis in long axons [5]. SPAST mutations are predominantly missense, nonsense, and splice-site variants; whole-gene deletions can also cause the disease. Loss of function (haploinsufficiency) is the primary pathogenic mechanism. Decreased microtubule-severing activity leads to impaired axonal transport and distal axonal degeneration, ultimately resulting in progressive spastic paraplegia [3,6]. There is currently no disease-modifying therapy for SPG4; clinical management is mainly symptomatic treatment of spasticity.
The p.Arg499His (R499H) variant is a missense mutation in the SPAST gene caused by a nucleotide substitution at c.1496G>A (NM_014946.4), resulting in the replacement of arginine (Arg) with histidine (His) at amino acid position 499 of the Spastin protein. This variant is located within the AAA domain of Spastin and may affect its normal function. It has been reported in multiple clinical studies to be associated with hereditary spastic paraplegia type 4 (SPG4). Affected individuals may exhibit infantile-onset symptoms, including lower limb spasticity and delayed motor development. Some cases may also present with dystonia, dysarthria, and cognitive impairment [7-8].
huSPAST-HA-R499H mice were generated using gene-editing technology by replacing the sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the human TAA stop codon, and the p.R499H (CGT to CAT) mutation was introduced into exon 13 of the human SPAST gene. This model can be used to investigate the pathogenesis of hereditary spastic paraplegia type 4 (SPG4) associated with the SPAST R499H mutation, as well as to support the development and efficacy evaluation of targeted therapeutics.
参考文献
Salinas S, et al. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008;7(12):1127-1138.
Ruano L, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174-183.
Fonknechten N, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9(4):637-644.
Zhao M, et al. Genetic and Clinical Profile of Chinese Patients with Autosomal Dominant Spastic Paraplegia. Mol Diagn Ther. 2019;23(6):781-789.
Roll-Mecak A, et al. Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin. Nature. 2008;451(7176):363-367.
Patrono C, et al. Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. J Neurol. 2002;249(2):200-205.
Nan H, et al. A p.Arg499His mutation in SPAST is associated with infantile-onset complicated spastic paraplegia: a case report and review of the literature. BMC Neurol. 2021 Nov 9;21(1):439.
Mo A, et al. Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST. Mov Disord. 2022 Dec;37(12):2440-2446.
系統作製戦略
The sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene was replaced with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the TAA stop codon of the human SPAST gene, and the p.R499H (CGT to CAT) mutation was introduced into human SPAST exon 13.

Figure 1. Gene editing strategy of huSPAST-HA-R499H mice.
適用分野
Research on the pathogenesis of hereditary spastic paraplegia type 4 (SPG4);
Screening, development, and preclinical in vivo evaluation of SPAST-targeted therapies.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
